AndroGel (Testosterone Topical) and Erythrocytosis: When to Call the Doctor

What Erythrocytosis Means on Testosterone Therapy

Erythrocytosis is a sustained increase in red blood cell mass, detected in clinical practice by a rising hematocrit or hemoglobin concentration. It differs from polycythemia vera, which is a myeloproliferative neoplasm driven by a JAK2 mutation. Testosterone-induced erythrocytosis is a secondary, dose-dependent pharmacologic effect.

The Endocrine Society's 2018 clinical practice guideline defines the action threshold as a hematocrit above 54%. At that level, whole-blood viscosity begins to rise sharply, and the theoretical risk of thromboembolic events increases [1]. A 2017 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that polycythemia/erythrocytosis accounted for a significant proportion of testosterone-related hematologic adverse events, with topical formulations generating fewer reports per prescription volume than intramuscular injections [2].

Not every patient who crosses 50% hematocrit is in danger. The clinical significance depends on the rate of rise, baseline cardiovascular risk, hydration status, and altitude. A man living in Denver at 5,280 feet may have a physiologically higher baseline hematocrit than a man at sea level. Context matters more than a single number.

Why AndroGel Raises Red Blood Cell Counts

Testosterone stimulates erythropoiesis through at least two parallel pathways. The first is suppression of hepcidin, the liver-derived peptide that limits intestinal iron absorption and macrophage iron recycling. Lower hepcidin means more iron available for hemoglobin synthesis [3]. A study published in The Journal of Clinical Endocrinology & Metabolism confirmed that testosterone administration suppresses hepcidin in a dose-dependent fashion, with measurable suppression within two weeks of initiating therapy [3].

The second pathway involves direct stimulation of renal erythropoietin (EPO) production. Testosterone upregulates hypoxia-inducible factor signaling in renal interstitial cells, boosting EPO secretion even in the absence of true tissue hypoxia [4]. A controlled trial by Bachman et al. (2014) demonstrated that graded testosterone doses produced linear increases in hemoglobin concentration, with the highest doses yielding hemoglobin increases of 1.0 to 1.5 g/dL above baseline in older men [4].

AndroGel specifically produces more stable serum testosterone levels compared to intramuscular cypionate, which causes a peak-and-trough pattern every one to two weeks. That pharmacokinetic stability translates to a lower magnitude of erythropoietic drive. The AndroGel 1.62% prescribing label reports polycythemia in 5.2% of treated patients in clinical trials, compared to rates of 10% to 40% reported with injectable testosterone cypionate in observational series [5][6].

Hematocrit Thresholds and What They Signal

The numbers on your lab report carry different clinical implications depending on where they fall. A hematocrit between 48% and 50% in a man on TRT is common and typically requires no intervention beyond ongoing monitoring. Between 50% and 54%, your prescribing clinician should increase monitoring frequency and consider whether dose adjustment is appropriate. Above 54% triggers a mandatory clinical decision.

The American Urological Association's 2018 testosterone guideline states: "If hematocrit is greater than 54%, clinicians should stop testosterone therapy and evaluate the patient for hypoxia and sleep apnea. Testosterone therapy should be restarted at a reduced dose once hematocrit has decreased to a safe level" [7]. This recommendation reflects a consensus position, not a threshold derived from a single randomized trial.

A practical decision framework for patients and clinicians:

• Hematocrit <50%: Continue current dose. Recheck at next scheduled interval.
• Hematocrit 50% to 52%: Increase hydration, confirm the patient is not dehydrated at the time of the draw. Recheck in 4 to 6 weeks.
• Hematocrit 52% to 54%: Consider dose reduction (e.g., switch from AndroGel 1.62% two pumps to one pump daily, or from 1% 7.5 g sachets to 5 g sachets). Recheck in 4 weeks.
• Hematocrit >54%: Hold AndroGel. Evaluate for secondary causes (sleep apnea, chronic lung disease, EPO-secreting tumors). Consider therapeutic phlebotomy. Restart at a lower dose only after hematocrit normalizes below 50%.

When to Call Your Doctor: The Red-Flag Symptoms

Some situations require a phone call the same day. Others require a trip to the emergency department. The distinction depends on symptom severity and tempo.

Call your prescriber within 24 hours if you experience:

• Persistent headache that does not respond to over-the-counter analgesics, especially if it worsens when lying flat
• New facial flushing or ruddy skin appearance that persists beyond exercise
• Unusually high blood pressure readings at home (systolic >150 mmHg or diastolic >95 mmHg) when those readings were previously controlled
• Progressive fatigue or cognitive sluggishness that paradoxically worsens despite being on testosterone (this can signal hyperviscosity rather than low testosterone)

Go to the emergency department if you develop:

• Sudden severe headache with visual changes (could indicate hypertensive crisis or, rarely, cerebral venous sinus thrombosis)
• Chest pain, pressure, or tightness, particularly with exertion
• Unilateral leg swelling with warmth and pain (possible deep vein thrombosis)
• Shortness of breath at rest or with minimal activity (possible pulmonary embolism)
• Transient weakness, numbness, or speech difficulty on one side of the body (possible transient ischemic attack or stroke)

The FDA's 2015 label change for all testosterone products added warnings about venous thromboembolism, reinforcing the clinical relevance of erythrocytosis as a contributing risk factor [8]. A meta-analysis by Houghton et al. (2024) pooling data from 11 RCTs found that testosterone therapy increased hematocrit-related adverse events (RR 5.18 to 95% CI 2.77 to 9.69) but did not find a statistically significant increase in major adverse cardiovascular events in the pooled analysis [9]. The TRAVERSE trial (N=5,246) confirmed this pattern: testosterone treatment increased erythrocytosis incidence while the primary composite cardiovascular endpoint was noninferior to placebo [10].

Dr. Shalender Bhasin, principal investigator of the Testosterone Trials (TTrials), has noted: "Erythrocytosis remains the most frequent dose-limiting adverse effect of testosterone therapy, and clinicians must monitor hematocrit systematically rather than waiting for symptoms to appear" [11].

How Clinicians Manage Erythrocytosis on AndroGel

Management follows a stepwise approach. The mildest intervention is dose reduction. Because AndroGel comes in metered-dose pumps (1.62% formulation delivers 20.25 mg per pump actuation) and single-use packets, titration is straightforward. Reducing from two pumps to one pump daily, or switching from the 1% 7.5 g packet to the 5 g packet, typically lowers steady-state testosterone levels enough to bring hematocrit back under 50% within 4 to 8 weeks.

If dose reduction alone is insufficient, or if the patient's testosterone level drops below the therapeutic range at the lower dose, clinicians may add therapeutic phlebotomy. Removing one unit (approximately 450 to 500 mL) of whole blood lowers hematocrit by roughly 3 percentage points [12]. The American Association of Clinical Endocrinologists' 2021 consensus statement supports phlebotomy as a temporizing measure but cautions against indefinite repeated phlebotomy as a substitute for proper dose adjustment [13].

Switching formulations is another option. Nasal testosterone (Natesto, 5.5 mg per nostril three times daily) produces short-duration testosterone peaks that may stimulate erythropoiesis less than sustained-release topicals. A 12-month open-label study of Natesto reported hematocrit elevations above 54% in only 1.1% of subjects, compared to the 5.2% rate seen with AndroGel 1.62% [14][5]. The tradeoff is inconvenience: three daily nasal applications versus one daily skin application.

The Endocrine Society's 2018 guideline also recommends evaluating for obstructive sleep apnea in any patient with persistent erythrocytosis on TRT. Dr. Abraham Morgentaler of Harvard Medical School has stated: "The combination of testosterone therapy and untreated sleep apnea creates a dual stimulus for erythropoiesis that can push hematocrit to dangerous levels. Treating the apnea first sometimes resolves the erythrocytosis entirely without changing the testosterone dose" [15].

How Long Erythrocytosis Takes to Develop and Resolve

Red blood cells have a lifespan of approximately 120 days. This biological clock governs both the onset and the resolution timeline of testosterone-induced erythrocytosis.

After starting AndroGel, hematocrit typically begins rising within 2 to 4 weeks and reaches a new steady state by 3 to 6 months. A longitudinal cohort study by Coviello et al. tracking hematocrit in men on various testosterone formulations found that 90% of patients who developed erythrocytosis did so within the first 6 months [16]. Late-onset erythrocytosis (after 12 months of stable dosing) should prompt evaluation for a superimposed cause such as new-onset sleep apnea, chronic lung disease, or an EPO-secreting renal lesion.

After discontinuing AndroGel, hematocrit declines gradually over 6 to 12 weeks as existing red blood cells complete their natural lifespan and are not replaced at the same rate. Therapeutic phlebotomy can accelerate this timeline. Patients who merely reduce the dose rather than stop entirely may see a plateau in hematocrit within 4 to 8 weeks.

The TRAVERSE trial's hematocrit substudy found that the median time to first hematocrit >54% was 8 months from randomization in the testosterone arm, with a cumulative incidence of 7.5% at 22 months versus 1.2% in the placebo arm [10]. This confirms that ongoing monitoring matters even after the first year.

Risk Factors That Increase Your Susceptibility

Not everyone on AndroGel develops erythrocytosis. Several factors raise the probability.

Age over 65. Older men have a higher prevalence of subclinical chronic lung disease and sleep-disordered breathing, both of which independently raise EPO. The Testosterone Trials (TTrials) enrolled men aged 65 and older and found that testosterone gel (1%, dose-adjusted to mid-normal range) increased hemoglobin by an average of 1.0 g/dL, with 4.7% exceeding the 54% hematocrit cutoff over 12 months [17].

Obstructive sleep apnea. The intermittent hypoxia of untreated OSA stimulates EPO independently of testosterone. The combination is additive. A cross-sectional analysis from the European Male Ageing Study reported that men with both low testosterone and undiagnosed OSA had higher baseline hematocrit values before any treatment [18].

Higher altitude residence. Living above 4,000 feet raises baseline hematocrit by 1 to 3 percentage points through chronic hypoxic EPO stimulation. Starting testosterone from this elevated baseline narrows the margin before reaching 54%.

Obesity and metabolic syndrome. Adipose tissue aromatizes testosterone to estradiol, which can paradoxically stimulate hepatic thrombopoietin. Obese men on TRT may also have undiagnosed obesity hypoventilation syndrome contributing to erythrocytosis.

Higher testosterone doses or supratherapeutic levels. The Bachman dose-response study showed a clear linear relationship: higher testosterone doses produce greater hemoglobin increases [4]. Ensuring that trough testosterone levels stay within the 450 to 700 ng/dL range (rather than pushing toward 900+ ng/dL) meaningfully reduces erythrocytosis risk.

Monitoring Schedule on AndroGel

The recommended monitoring cadence, drawn from the Endocrine Society 2018 guideline, is:

• Baseline (before starting): Complete blood count with hematocrit, serum testosterone, PSA, lipid panel, hepatic panel, basic metabolic panel.
• 3 to 6 months after initiation: Repeat hematocrit and testosterone level. This is the highest-risk window for early erythrocytosis.
• 12 months: Repeat full monitoring panel including hematocrit, testosterone trough level, PSA, and metabolic labs.
• Annually thereafter: Hematocrit, testosterone level, PSA, and clinical assessment. Increase frequency to every 3 months if hematocrit is trending upward (e.g., rising from 48% toward 52% on consecutive draws).

Hydration status at the time of the blood draw matters. Dehydration concentrates the blood and can artificially raise hematocrit by 2 to 3 percentage points. Clinicians often ask patients to drink 16 to 24 ounces of water in the hour before the draw and avoid caffeine and alcohol for 12 hours prior.

Why Topical Gel Carries Lower Risk Than Injections

The pharmacokinetic profile of AndroGel explains its relative erythrocytosis advantage. After applying 40.5 mg of AndroGel 1.62% (two pump actuations) to the upper arms and shoulders, testosterone absorbs through the skin over several hours. Serum levels peak at approximately 4 to 8 hours post-application and remain within a relatively narrow range throughout the day [5].

Intramuscular testosterone cypionate (typically 100 to 200 mg every 1 to 2 weeks), by contrast, produces a sharp supraphysiologic peak within 24 to 48 hours, followed by a gradual decline into the hypogonadal range just before the next injection. That supraphysiologic peak maximally stimulates hepcidin suppression and EPO secretion. A comparative pharmacokinetic study published in Andrology found that peak testosterone levels were 40% to 60% higher after intramuscular injection than the daily peak achieved by transdermal gel, and the area-under-the-curve above the 1 to 000 ng/dL threshold was substantially greater [19].

This pharmacokinetic difference explains why observational registries consistently report lower erythrocytosis incidence with gels (3% to 7%) compared to injections (10% to 40%), though the exact figures vary by study design and hematocrit threshold used [6][19]. Patients who are already on intramuscular testosterone and developing erythrocytosis may benefit from switching to AndroGel as a first-line management strategy before resorting to dose reduction or phlebotomy.

The most recent hematocrit above 54% mandating a same-day clinical decision was observed in 7.5% of the TRAVERSE testosterone arm at a median follow-up of 22 months, using a mixed population of gel and injectable users [10].